• Breast Cancer
    • Gunter Von Minckwitz
    • Gunter von Minckwitz: Influence Statistics

      Gunter von Minckwitz

      Gunter von Minckwitz

      Show email address

      GBG, Neu-Isenburg, Germany | German Breast Group, Neu-Isenburg, Germany | German Breast Group, Neu-Isenburg, Germany. | German Breast Group (GBG), Neu-Isenburg, Germany; | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Gunter von Minckwitz:Expert Impact

      Concepts for whichGunter von Minckwitzhas direct influence:Breast cancer,Neoadjuvant chemotherapy,Metastatic breast cancer,Neoadjuvant therapy,Neoadjuvant treatment,Pathological complete response,Primary breast cancer,Breast cancer patients.

      Gunter von Minckwitz:KOL impact

      Concepts related to the work of other authors for whichfor which Gunter von Minckwitz has influence:Breast cancer,Neoadjuvant chemotherapy,Tumor cells,Bone marrow,Zoledronic acid,Lymph node,Estrogen receptor.

      KOL Resume for Gunter von Minckwitz


      GBG, Neu-Isenburg, Germany


      German Breast Group (GBG), Neu-Isenburg, Germany;


      German Breast Group Forschungs GmbH, Neu-Isenburg, Germany


      German Breast Group, Neu-Isenburg, Universitäts-Klinikum, Heidelberg, Germany.

      Department of Gynecology and Obstetrics, University Hospital, Frankfurt.


      Medicine and Research, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany


      German Breast Group GmbH, Neu-Isenburg 63263, Germany;, (N.B.);, (G.v.M.);, (S.L.)


      GBG Forschungs GmbH, Neu-Isenburg and University Women’s Hospital Frankfurt, Frankfurt, Germany

      German Breast Group, Neu-Isenburg; Universitäts-Klinikum Frankfurt; Senologische Onkologie, Düsseldorf.


      University Women’s Hospital Frankfurt, Frankfurt, Germany

      Department of Obstetrics and Gynecology, Goethe-Universität, Frankfurt/Main

      Breast International Group Executive Board.

      GBG Forschungs GmbH Neu-Isenburg, Universitäts-Frauenklinik Frankfurt.


      Gunter von Minckwitz, Keyur Mehta, and Sibylle Loibl, Headquarters, German Breast Group, Neu-Isenburg; Jens Uwe Blohmer, St Gertrauden Krankenhaus, Berlin); Serban Dan Costa, Universitäts-Frauenklinik, Magdeburg; Carsten Denkert, Institute for Pathology, Charite, Berlin; Holger Eidtmann, Universitäts-Frauenklink, Kiel; Wolfgang Eiermann and Claus Hanusch, Klinikum zum Roten Kreuz, Munich; Bernd Gerber, Universitäts-Frauenklinik, Rostock; Jörn Hilfrich, Henrietten-Stiftung, Hanover; Jens Huober,...

      Headquarters, German Breast Group, Neu-Isenburg, Germany

      German Breast Group, Neu-Isenburg, Universitäts-Frauenklinik Frankfurt, Frankfurt

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Gunter von Minckwitz is among the top experts in the world.
      Concept World rank
      monoclonal german breast #1
      response cycles #1
      trastuzumab baseline #1
      preoperative chemotherapy doxorubicin #1
      chemotherapy 17 7 #1
      pcr 086 95 #1
      tac nx #1
      gcsf tamoxifen #1
      upfront pegfilgrastim #1
      improved dfs zoledronate #1
      safety treatment phase #1
      responding patients pcr #1
      adoc gcsf #1
      biosimilarity biosimilar candidate #1
      trastuzumab partial remission #1
      oblimersen combined #1
      knowledge lsg #1
      multivariable analysis model #1
      leucovorin liver function #1
      clinically nodepositive disease #1
      neoadjuvant vinorelbine #1
      natan #1
      breast commission #1
      slnb lsg #1
      lower pcr #1
      mbc humanized antineoplastic #1
      bevacizumab chemotherapy arm #1
      gbg big #1
      positive receptor #1
      trastuzumab german breast #1
      tac patients #1
      mbc secondline pfs #1
      3week cycles #1
      bmf ttp #1
      mifufo salvage chemotherapy #1
      cmf firstline treatment #1
      tamoxifen docetaxel regimen #1
      improved dfs letrozole #1
      carboplatin addition #1
      monoclonal ductal #1
      238 patients chemotherapy #1
      paclitaxel neoadjuvant #1
      ciprofloxacin colonystimulating factor #1
      capecitabine carcinoma ductal #1
      4 cycles tac #1
      estrogen receptors trastuzumab #1
      oblimersen combination #1
      longacting gcsfs patients #1
      arm sentinellymphnode biopsy #1
      macrophages breast #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Gunter von Minckwitz

      KOL-Index: 29416

      BACKGROUND: Although several randomised trials in patients with triple-negative breast cancer have shown that the addition of carboplatin, with or without poly(ADP-ribose) polymerase (PARP) inhibitors, to neoadjuvant chemotherapy increases the likelihood of achieving a pathological complete response, the use of these therapies in this setting has remained controversial. The BrighTNess trial was designed to assess the addition of the PARP inhibitor veliparib plus carboplatin or ...

      Known for Carboplatin Paclitaxel | Neoadjuvant Chemotherapy | 3 Trial | Negative Breast | Parp Inhibitor Veliparib
      KOL-Index: 27269

      BACKGROUND: Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer.

      METHODS: We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 495 centres in Europe, Asia, Australia, New Zealand, ...

      Known for Neratinib Patients | Positive Breast | 3 Trial | Adjuvant Therapy | 1 Grade
      KOL-Index: 25708

      BACKGROUND: ABP 980 (Amgen Inc, Thousand Oaks, CA, USA) is a biosimilar of trastuzumab, with analytical, functional, and pharmacokinetic similarities. We compared the clinical safety and efficacy of ABP 980 with that of trastuzumab in women with HER2-positive early breast cancer.

      METHODS: We did a randomised, multicentre, double-blind, active-controlled equivalence trial at 97 study centres in 20 countries, mainly in Europe and South America. Eligible women were aged 18 years or older, ...

      Known for Abp 980 | Reference Trastuzumab | Lilac Study | Early Breast | Phase 3
      KOL-Index: 24366

      BACKGROUND: The optimum timing of sentinel-lymph-node biopsy for breast cancer patients treated with neoadjuvant chemotherapy is uncertain. The SENTINA (SENTinel NeoAdjuvant) study was designed to evaluate a specific algorithm for timing of a standardised sentinel-lymph-node biopsy procedure in patients who undergo neoadjuvant chemotherapy.

      METHODS: SENTINA is a four-arm, prospective, multicentre cohort study undertaken at 103 institutions in Germany and Austria. Women with breast cancer ...

      Known for Neoadjuvant Chemotherapy | Node Biopsy | Breast Cancer | Detection Rate | 95 Patients
      KOL-Index: 21246

      Importance: The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 germline mutation status affects treatment outcome remains elusive.

      Objective: To determine whether BRCA1 and BRCA2 germline mutation status affects therapy response in patients with TNBC.

      Design, ...

      Known for Brca1 Brca2 | Mutation Status | Carboplatin Patients | Pathological Complete Response | Secondary Analysis
      KOL-Index: 20595

      BACKGROUND: In metastatic breast cancer, nab-paclitaxel has been shown to significantly increase progression-free survival compared with solvent-based paclitaxel. The GeparSepto (GBG 69) trial assessed whether weekly nab-paclitaxel could increase the proportion of patients achieving pathological complete response compared with weekly solvent-based paclitaxel, both followed by epirubicin plus cyclophosphamide as neoadjuvant treatment.

      METHOD: In a phase 3 randomised trial, we enrolled ...

      Known for Based Paclitaxel | 3 Trial | Neoadjuvant Chemotherapy | Early Breast Cancer | Pathological Complete Response
      KOL-Index: 20276

      BACKGROUND: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol-defined 5-year follow-up sensitivity analysis and long-term toxicity findings.

      METHODS: In this ongoing randomised, double-blind, placebo-controlled, phase 3 trial, eligible women aged 18 ...

      Known for Positive Breast | 1 Year | Neratinib Placebo | Adjuvant Therapy | Disease Recurrence
      KOL-Index: 19807

      Background: In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival data and the potential prognostic and predictive role of homologous recombination deficiency (HRD).

      Patients and methods: Patients were randomized to paclitaxel plus nonpegylated liposomal doxorubicin (Myocet®) (PM) or PM plus carboplatin ...

      Known for Hrd Score | Patients Tnbc | Neoadjuvant Chemotherapy | Hazard Ratio | Carboplatin Pmcb
      KOL-Index: 19600

      BACKGROUND: Pathological complete response has been proposed as a surrogate endpoint for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (EFS), and overall survival (OS). We had four key objectives: to establish the association between pathological complete response and EFS and OS, to establish the definition of pathological complete response that correlates best with long-term outcome, to identify the breast cancer subtypes in which ...

      Known for Pathological Complete Response | Ypt0 Ypn0 Ypt0 | Pooled Analysis | Breast Chemotherapy | Surrogate Endpoint
      KOL-Index: 18643

      BACKGROUND: Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more effective than tamoxifen for women with hormone-receptor-positive ductal carcinoma in situ (DCIS). Here, we compare the efficacy of anastrozole with that of tamoxifen in postmenopausal women with hormone-receptor-positive DCIS.

      METHODS: In a ...

      Known for Postmenopausal Women | Anastrozole Tamoxifen | Breast Cancer | Ductal Carcinoma | Positive Dcis
      KOL-Index: 18588

      BACKGROUND: Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. In this trial, we investigated whether pertuzumab, when added to adjuvant trastuzumab and chemotherapy, improves outcomes among patients with HER2-positive early breast ...

      Known for Pertuzumab Placebo | Breast Cancer | Trastuzumab Chemotherapy | Hazard Ratio | Early Her2
      KOL-Index: 18556

      BACKGROUND: Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, trastuzumab, and a platinum salt for HER2-positive breast cancer. We therefore aimed to assess the efficacy of the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive breast cancer.

      METHODS: Patients with previously untreated, non-metastatic, stage II-III, triple-negative ...

      Known for Neoadjuvant Carboplatin | Breast Cancer | 2 Trial | Randomised Phase | Patients Triple
      KOL-Index: 18435

      BACKGROUND: Approximately 30% of the patients with primary breast cancer who have no axillary lymph node involvement (i.e., lymph node negative) at the time of surgery will relapse within 10 years; 10%-20% of the patients with distant metastases will be lymph node negative at surgery. Axillary lymph node dissection, as a surgical procedure, is associated with frequent complications. A possible alternative to nodal dissection in terms of prognosis may be the immunocytochemical detection ...

      Known for Bone Marrow | Primary Surgery | Cancer Cells | Nodal Status | Lymph Node
      KOL-Index: 18418

      BACKGROUND: We compared the efficacy and safety of the addition of lapatinib versus trastuzumab to anthracycline-taxane-based neoadjuvant chemotherapy.

      METHODS: In the GeparQuinto randomised phase 3 trial, patients with untreated HER2-positive operable or locally advanced breast cancer were enrolled between Nov 7, 2007, and July 9, 2010. Patients were eligible if their tumours were classified as cT3/4a-d, or hormone receptor (HR)-negative, HR-positive with clinically node-positive and ...

      Known for Trastuzumab Lapatinib | 3 Trial | Randomised Phase | Based Chemotherapy | Pathological Complete Response
      KOL-Index: 18057

      BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are predictive for response to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, but their role in luminal breast cancer and the effect of TILs on prognosis in all subtypes is less clear. Here, we assessed the relevance of TILs for chemotherapy response and prognosis in patients with TNBC, HER2-positive breast cancer, and luminal-HER2-negative breast cancer.

      METHODS: Patients with primary ...

      Known for Neoadjuvant Therapy | Pooled Analysis | Patients Tnbc | Her2positive Breast Cancer | Low Tils

      Key People For Breast Cancer

      Top KOLs in the world
      Ahmedin M Jemal
      united states breast cancer addis ababa
      Gabriel N Hortobagyi
      breast cancer neoadjuvant chemotherapy estrogen receptors
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      Charles M Perou
      breast cancer gene expression intrinsic subtypes
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      Jacques Ferlay
      cancer incidence global burden latin america

      GBG, Neu-Isenburg, Germany | German Breast Group, Neu-Isenburg, Germany | German Breast Group, Neu-Isenburg, Germany. | German Breast Group (GBG), Neu-Isenburg, Germany; | Department of Medical Oncology, University of Ulm, Ulm, Germany

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.